Published in Proc Natl Acad Sci U S A on December 18, 2001
Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc Natl Acad Sci U S A (2002) 1.58
Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat Neurosci (2012) 1.55
Impaired antibody synthesis after spinal cord injury is level dependent and is due to sympathetic nervous system dysregulation. Exp Neurol (2007) 1.52
Role of myelin-associated inhibitors in axonal repair after spinal cord injury. Exp Neurol (2011) 1.21
Peripherally-derived BDNF promotes regeneration of ascending sensory neurons after spinal cord injury. PLoS One (2008) 0.93
Neural stem cell niches in health and diseases. Curr Pharm Des (2012) 0.91
Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury. PLoS One (2012) 0.86
Advances in regenerative therapies for spinal cord injury: a biomaterials approach. Neural Regen Res (2015) 0.77
Immunization with neural derived peptides plus scar removal induces a permissive microenvironment, and improves locomotor recovery after chronic spinal cord injury. BMC Neurosci (2017) 0.75
Abstracts of the 13th Meeting of the European Neurological Society. 14-18 June 2003, Istanbul, Turkey. J Neurol (2003) 0.75
T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol (1978) 28.92
Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol (1996) 5.46
Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature (2000) 5.22
Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med (1999) 3.13
Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev (1996) 2.98
Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature (1995) 2.93
Vascular events after spinal cord injury: contribution to secondary pathogenesis. Phys Ther (2000) 2.61
Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med (1998) 2.31
Experimental autoimmune encephalomyelitis (EAE) mediated by T cell lines: process of selection of lines and characterization of the cells. J Immunol (1982) 1.84
The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injury. Exp Neurol (1995) 1.78
T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol (1993) 1.74
Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. J Neurosci (1999) 1.70
Protective autoimmunity is a physiological response to CNS trauma. J Neurosci (2001) 1.64
Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci (2000) 1.62
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A (2000) 1.61
Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A (2001) 1.61
Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma (1999) 1.55
Locomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. J Neurosci (2001) 1.46
Regeneration of lesioned corticospinal tract fibers in the adult rat induced by a recombinant, humanized IN-1 antibody fragment. J Neurosci (2000) 1.45
Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci (2001) 1.35
Functional switch between motor tracts in the presence of the mAb IN-1 in the adult rat. Proc Natl Acad Sci U S A (2001) 1.27
Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. J Neurosci (2001) 1.23
Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol Med (2001) 1.22
Kinetics of facial motoneuron loss following facial nerve transection in severe combined immunodeficient mice. J Neurosci Res (2000) 1.21
Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest (2001) 1.20
Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol (1998) 1.20
Repulsive factors and axon regeneration in the CNS. Curr Opin Neurobiol (2001) 1.19
Spinal cord injury-induced inflammation: a dual-edged sword. Prog Brain Res (2000) 1.11
Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet (2000) 1.10
Transplantation of activated macrophages overcomes central nervous system regrowth failure. FASEB J (1996) 1.10
Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J Neuroimmunol (1997) 1.09
Nogo-A, a potent inhibitor of neurite outgrowth and regeneration. Biol Chem (2000) 1.02
Glial inhibition of nerve regeneration in the mature mammalian CNS. Glia (2000) 0.98
NI-35/250/nogo-a: a neurite growth inhibitor restricting structural plasticity and regeneration of nerve fibers in the adult vertebrate CNS. Glia (2000) 0.90
Nogo domains and a Nogo receptor: implications for axon regeneration. Neuron (2001) 0.87
Spinal cord regeneration. Science (1996) 0.84
Persistence of rubrospinal projections following spinal cord injury in the rat. J Comp Neurol (1994) 0.81
Assessment of spinal cord injury by counting corticospinal and rubrospinal neurons. Brain Res (1987) 0.79
Encephalitogenic and neuritogenic T cell responses to the myelin-associated glycoprotein (MAG) in the Lewis rat. J Neuroimmunol (1999) 0.77
The UCSC Genome Browser Database. Nucleic Acids Res (2003) 32.84
Regulation of tumor antigen synthesis by simain virus 40 gene A. J Virol (1975) 9.93
Positive control of transcription initiation in bacteria. Annu Rev Genet (1984) 8.74
Isolation of the bacteriophage lambda receptor from Escherichia coli. J Bacteriol (1973) 7.67
Location of the maltose A and B loci on the genetic map of Escherichia coli. J Bacteriol (1966) 5.97
Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med (2001) 5.48
Maltose transport in Escherichia coli K12. A comparison of transport kinetics in wild-type and lambda-resistant mutants as measured by fluorescence quenching. Eur J Biochem (1976) 5.25
A role for mRNA secondary structure in the control of translation initiation. Nature (1982) 5.01
Use of gene fusions to study outer membrane protein localization in Escherichia coli. Proc Natl Acad Sci U S A (1977) 3.78
The adsorption of coliphage lambda to its host: effect of variations in the surface density of receptor and in phage-receptor affinity. J Mol Biol (1976) 3.75
Genetic analysis of the maltose A region in Escherichia coli. J Bacteriol (1969) 3.52
Escherichia coli mutants impaired in maltodextrin transport. J Bacteriol (1979) 3.51
Dominant constitutive mutations in malT, the positive regulator gene of the maltose regulon in Escherichia coli. J Mol Biol (1978) 3.46
Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet (1991) 3.37
[Existence in Escherichia coli K 12 of a common regulation of the biosynthesis of bacteriophage receptors and maltose metabolism]. Ann Inst Pasteur (Paris) (1967) 3.33
Pleiotropic mutations rendering Escherichia coli K-12 resistant to bacteriophage TP1. J Bacteriol (1980) 3.31
Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med (1999) 3.13
Patterns of polymorphism and linkage disequilibrium for cystic fibrosis. Genomics (1987) 3.03
Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. Ann Thorac Surg (1994) 3.00
Structure of the malB region in Escherichia coli K12. I. Genetic map of the malK-lamB operon. Mol Gen Genet (1979) 2.99
[Phenotypic expression and genetic localization of mutations affecting maltose metabolism in Escherichia coli K 12]. Ann Inst Pasteur (Paris) (1967) 2.83
Structure of the malB region in Escherichia coli K12. II. Genetic map of the malE,F,G operon. Mol Gen Genet (1979) 2.83
Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet (2001) 2.70
Complementation studies in the maltose-A region of the Escherichia coli K12 genetic map. J Mol Biol (1971) 2.60
malB region in Escherichia coli K-12: characterization of new mutations. J Bacteriol (1974) 2.56
SCIM--spinal cord independence measure: a new disability scale for patients with spinal cord lesions. Spinal Cord (1997) 2.55
CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Hum Genet (2001) 2.51
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol (1993) 2.49
Intergration of the receptor for bacteriophage lambda in the outer membrane of Escherichia coli: coupling with cell division. J Bacteriol (1975) 2.47
Mutations that affect lamB gene expression at a posttranscriptional level. Proc Natl Acad Sci U S A (1981) 2.46
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
Mutations altering the cellular localization of the phage lambda receptor, an Escherichia coli outer membrane protein. Proc Natl Acad Sci U S A (1978) 2.37
Studies of RFLP closely linked to the cystic fibrosis locus throughout Europe lead to new considerations in populations genetics. Hum Genet (1990) 2.33
Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med (1998) 2.31
The use of gene fusions to study the expression of malT the positive regulator gene of the maltose regulon. J Mol Biol (1979) 2.27
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
Control of expression of the pyr genes in Salmonella typhimurium: effects of variations in uridine and cytidine nucleotide pools. J Bacteriol (1975) 2.24
[The impact of the implementation of staying in the United Kingdom for six months or more as donor exclusion criteria on the donor base of the Basque Country]. Med Clin (Barc) (2001) 2.22
[Maltodextrin phosphorylase of Escherichia coli]. Eur J Biochem (1967) 2.21
Sequence information within the lamB genes in required for proper routing of the bacteriophage lambda receptor protein to the outer membrane of Escherichia coli K-12. J Mol Biol (1982) 2.20
A technique for integrating any DNA fragment into the chromosome of Escherichia coli. Gene (1984) 2.11
Phosphoglucomutase mutants of Escherichia coli K-12. J Bacteriol (1971) 2.07
The enigma of myelin-associated growth inhibitors in spontaneously regenerating nervous systems. Trends Neurosci (1994) 2.06
Protein Ia and the lamB protein can replace each other in the constitution of an active receptor for the same coliphage. Proc Natl Acad Sci U S A (1978) 2.06
Colicin E2 release: lysis, leakage or secretion? Possible role of a phospholipase. EMBO J (1984) 2.02
Extracellular pullulanase of Klebsiella pneumoniae is a lipoprotein. J Bacteriol (1986) 2.02
A signal sequence is not sufficient to lead beta-galactosidase out of the cytoplasm. Nature (1980) 2.00
Induction of enzymes involed in the catabolism of deoxyribonucleosides and ribonucleosides in Escherichia coli K 12. Eur J Biochem (1971) 1.97
Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med (1998) 1.93
Mutations allowing growth on maltose of Escherichia coli K 12 strains with a deleted malT gene. Mol Gen Genet (1971) 1.92
Systematic review of the treatment and prognosis of the odontogenic keratocyst. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.85
Impact of internal mammary artery conduits on operative mortality in coronary revascularization. Ann Thorac Surg (1994) 1.85
Alcohol dehydrogenase-negative mutants in Drosophila: defects at the structural locus? Genetics (1976) 1.84
On the significance of the retention of ligand by protein. Proc Natl Acad Sci U S A (1975) 1.83
Energy-coupling of the transport system of Escherichia coli dependent on maltose-binding protein. Eur J Biochem (1977) 1.83
Reversible interaction between coliphage lambda and its receptor protein. J Mol Biol (1975) 1.82
Adherence and psychological adjustment among women at high risk for breast cancer. Breast Cancer Res Treat (1993) 1.79
Characterization and expression of the structural gene for pullulanase, a maltose-inducible secreted protein of Klebsiella pneumoniae. J Bacteriol (1985) 1.78
Managing medical mistakes: ideology, insularity and accountability among internists-in-training. Soc Sci Med (1984) 1.78
Restriction map of the Escherichia coli malA region and identification of the malT product. J Bacteriol (1980) 1.77
Fractures of the spine in diffuse idiopathic skeletal hyperostosis. Clin Orthop Relat Res (1991) 1.76
Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA (1991) 1.75
Occurrence of the bacteriophage lambda receptor in some enterobacteriaceae. J Virol (1975) 1.74
Molecular basis of choroideremia (CHM): mutations involving the Rab escort protein-1 (REP-1) gene. Hum Mutat (1997) 1.74
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut (2005) 1.72
Guidelines for the retention, storage, and use of residual dried blood spot samples after newborn screening analysis: statement of the Council of Regional Networks for Genetic Services. Biochem Mol Med (1996) 1.72
Characterization of Erwinia chrysanthemi extracellular proteases: cloning and expression of the protease genes in Escherichia coli. J Bacteriol (1987) 1.71
Magnetic resonance image-directed stereotactic neurosurgery: use of image fusion with computerized tomography to enhance spatial accuracy. J Neurosurg (1995) 1.70
The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet (1998) 1.67
Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol (1977) 1.66
Protective autoimmunity is a physiological response to CNS trauma. J Neurosci (2001) 1.64
Understanding physicians' intentions to withdraw from practice: the role of job satisfaction, job stress, mental and physical health. Health Care Manage Rev (2001) 1.63
Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci (2000) 1.62
Uridine phosphorylase from Escherichia coli. Physical and chemical characterization. Eur J Biochem (1977) 1.61
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A (2000) 1.61
Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A (2001) 1.61
Inflammation after axonal injury has conflicting consequences for recovery of function: rescue of spared axons is impaired but regeneration is supported. J Neuroimmunol (1994) 1.60
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol (1997) 1.60
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
The effect of nalidixic acid on the expression of some genes in Escherichia coli K-12. Biochem Biophys Res Commun (1975) 1.59
Characterization of fat-storing cell lines derived from normal and CCl4-cirrhotic livers. Differences in the production of interleukin-6. Lab Invest (1991) 1.56
Essential and nonessential sequences in malPp, a positively controlled promoter in Escherichia coli. J Bacteriol (1985) 1.54
Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. Br J Cancer (1999) 1.52
Catabolite repression in Escherichia coli mutants lacking cyclic AMP. Mol Gen Genet (1978) 1.50
Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J Rheumatol (2000) 1.50
Evidence for a coupling of synthesis and export of an outer membrane protein in Escherichia coli. EMBO J (1983) 1.50
Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med (1996) 1.48
Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat (2000) 1.48
Genetic heterogeneity among blue-cone monochromats. Am J Hum Genet (1993) 1.47
Identification of human plasma cholinesterase variants using molecular biological techniques. Acta Anaesthesiol Scand (1995) 1.47
RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci (2000) 1.46
Nonsense mutations in the maltose A region of the genetic map of Escherichia coli. J Bacteriol (1969) 1.45
Physical fine mapping of the choroideremia locus using Xq21 deletions associated with complex syndromes. Genomics (1989) 1.44
Detection of hepatitis B and hepatitis C viral sequences in fulminant hepatic failure of unknown etiology. Am J Clin Pathol (1995) 1.43
Quantitative CT analysis of brain morphometry in adult Down's syndrome at different ages. Neurology (1987) 1.43
Naturally conceived twins with monochorionic placentation have the highest risk of fetal loss. Ultrasound Obstet Gynecol (2006) 1.42
Glutaryl-CoA dehydrogenase mutations in glutaric acidemia (type I): review and report of thirty novel mutations. Hum Mutat (1998) 1.42